Spago Nanomedical
0,7 SEK -1,96 %Vær den første som følger denne virksomhed
Spago Nanomedical conducts research and development in cancer diagnostics. The company conducts various development projects based on its proprietary nanomaterials whose potential is found in making tumours visible, and enabling internal radiation therapy of cancer. The company was founded in 2007 and is based in Lund.
Omsætning
1,05 mio.
EBIT %
-3.759,05 %
P/E
-
Udbytteafkast, %
-
Kursmål
-
Anbefaling
-
Opdateret
-
First North Stockholm
SPAGO
Daglig lav / høj pris
0,7 / 0,738
SEK
Markedsværdi
63,66 mio. SEK
Aktieomsætning
41,9 t SEK
Volumen
59 t
Finanskalender
Delårsrapport
23.08.2023
Delårsrapport
08.11.2023
Viser Alle indholdstyper